MIM1
Based on 1 Customer Validation
MIM-1 is an inhibitor of myeloid cell factor 1 (Mcl-1).
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 509102-00-5
- Formula: C17H21N3O3S
- Molecular Weight:347.43
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
|
Mcl-1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| B-ALL | IC50 |
4.2 μM
Compound: MIM1
|
Cytotoxicity against human B-ALL cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay
Cytotoxicity against human B-ALL cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay
|
[PMID: 29407973] |
| Leukemia cell | IC50 |
4.78 μM
Compound: 17
|
Inhibition of FITC-labeled Bid BH3 peptide binding to GST-tagged MCL1 harboring N-terminal and C-terminal point mutant (unknown origin) expressed in Escherichia coli Bl21(DE3) cells by fluorescence polarization assay
Inhibition of FITC-labeled Bid BH3 peptide binding to GST-tagged MCL1 harboring N-terminal and C-terminal point mutant (unknown origin) expressed in Escherichia coli Bl21(DE3) cells by fluorescence polarization assay
|
10.1039/C5MD00582E |
MIM-1 selectively targets the BH3 binding groove of Mcl-1, with Bak-dependent apoptotic activity. To estimate the sensitivity of HA and T98G cells to the apoptosis inhibitor MIM-1, the colorimetric MTT assay is used to detect cell viability and to determine the IC50 value. The IC50 value of the HA cell line is almost 5-fold lower (16.10 μM) compared with the IC50 of the T98G cell line (80.20 μM) after MIM-1 inhibitor treatment.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 509102-00-5
-
Appearance Solid
-
Molecular Weight 347.43
-
Formula C17H21N3O3S
-
Color White to off-white
-
SMILES
OC1=C(O)C(/C=N/N2/C(SC=C2C)=N/C3CCCCC3)=CC=C1O
-
Synonyms
Inhibitor of Mcl-1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 50 mg/mL (143.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.99 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.99 mM); Suspended solution
This protocol yields a suspended solution of ≥ 2.08 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
The IC50 value, defined as the concentration that reduces the global growth of cells by 50%, is determined for the apoptosis inhibitors ABT-737 and MIM-1, individually, for the human astrocyte (HA) and human GB (T98G) cell lines. The apoptosis inhibitor concentrations and treatment time periods are selected experimentally according to preliminary experiments. The final ABT-737 treatment is performed with 10-fold increasing concentrations in the range of 0.001-100 µM, and the final MIM-1 treatment is performed with 4-fold increasing concentrations in the range of 0.4-400 µM, for 48 h. The biochemical colorimetric MTT assay, based on the enzymatic conversion of MTT to a violet formazan salt, is used to assess the viability of the HA and T98G cells. Briefly, the cells in culture medium are seeded (3.5×103 cells/well for the HA cell line, 3.0×103 cells/well for T98G cell line) in 96-well microtiter plates. On the third day, the medium is changed to culture medium supplemented with the apoptosis inhibitor ABT-737 or MIM-1 at varied concentrations and incubation continued for another two days. After the treatment with the apoptosis inhibitors, cells are rinsed once with Dulbeccos phosphate buffer saline (DPBS) and further incubated in medium supplemented with 0.5 mg/mL MTT in a humidified atmosphere for 6 h. During a subsequent incubation for 16 h in medium containing SDS [5% (w/v)], the precipitated formazan, the amount of which is proportional to the number of live cells, is solubilized. The absorbance of the formazan-containing solution is measured at 540 nm using an ELISA plate reader. The absorbance is also determined for the medium of the control cells not exposed to the apoptosis inhibitors. The percentage of cell viability is calculated relative to the untreated control cells. The IC50 values are determined for both human brain cell lines after individual apoptosis inhibitor treatment.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8783 mL | 14.3914 mL | 28.7828 mL | 71.9569 mL |
| 5 mM | 0.5757 mL | 2.8783 mL | 5.7566 mL | 14.3914 mL | |
| 10 mM | 0.2878 mL | 1.4391 mL | 2.8783 mL | 7.1957 mL | |
| 15 mM | 0.1919 mL | 0.9594 mL | 1.9189 mL | 4.7971 mL | |
| 20 mM | 0.1439 mL | 0.7196 mL | 1.4391 mL | 3.5978 mL | |
| 25 mM | 0.1151 mL | 0.5757 mL | 1.1513 mL | 2.8783 mL | |
| 30 mM | 0.0959 mL | 0.4797 mL | 0.9594 mL | 2.3986 mL | |
| 40 mM | 0.0720 mL | 0.3598 mL | 0.7196 mL | 1.7989 mL | |
| 50 mM | 0.0576 mL | 0.2878 mL | 0.5757 mL | 1.4391 mL | |
| 60 mM | 0.0480 mL | 0.2399 mL | 0.4797 mL | 1.1993 mL | |
| 80 mM | 0.0360 mL | 0.1799 mL | 0.3598 mL | 0.8995 mL | |
| 100 mM | 0.0288 mL | 0.1439 mL | 0.2878 mL | 0.7196 mL |